Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
Optimer reports $62.4 million in DIFICID® (fidaxomicin) tablets net product sales for 2012
JERSEY CITY, N.J., Feb. 28, 2013 /PRNewswire/ — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012.
- 2012 DIFICID net product sales in the U.S. and Canada of $62.4 million, compared to $21.5 million in 2011
- A 14.3% increase in U.S. and Canadian DIFICID shipments in the fourth quarter, resulting in net sales of $16.8 million
- 2012 contract revenue from collaborations, which include up-front payments, milestones, royalties and product sales, were $39.1 million
- 2012 total revenues were $101.5 million
- Cash, cash equivalents and short-term investments at December 31, 2012 totaled $124.0 million
- 2012 net loss was $37.0 million, or $0.78 per share, and 2012 net income for the fourth quarter was $1.0 million, $0.02 per share
“2012 was an exciting year for Optimer. DIFICID is now available in over a dozen countries,” said Dr. Henry McKinnell, Optimer’s CEO and Chairman of the Board. “In the U.S. we will be focusing on improving the formulary status of DIFICID in the hospital marketplace and on expanding the use of this important new medicine in all channels.”
Total revenue for the years ended December 31, 2012 and 2011 was $101.5 million and $145.0 million, respectively. Total revenue for the fourth quarter 2012 and 2011 was $19.5 million and $64.6 million, respectively. The decreases were due to a reduction in contract revenue, which in 2011 included $122.7 million from the Astellas Pharma Europe (APEL) agreement, offset by increases in DIFICID net product sales.
DIFICID net product sales in the U.S. and Canada for the year and quarter ended December 31, 2012 were $62.4 million and $16.8 million, respectively. We recognize product sales of DIFICID upon delivery of product to our wholesalers. The increase in DIFICID net product sales in 2012 reflects higher demand for DIFICID, as well as a full year of sales. DIFICID was launched in July 2011.
Contract revenue for the years ended December 31, 2012 and 2011 was $39.1 million and $122.7 million, respectively, a decrease of $83.6 million. Contract revenue is generated from collaboration partners and includes up-front and milestone payments, royalties and product sales. In 2011, contract revenue included a $69.2 million up-front payment from APEL and a $53.5 million milestone upon EMA approval of DIFICLIR(TM). Contract revenue in 2012 included a $19.9 million up-front payment from Astellas Japan and a $12.6 million milestone payment from APEL in association with the first commercial sale of DIFICLIR in an APEL territory. Contract revenues in 2012 also included inventory shipments to our collaboration partners and royalty income from APEL.
Research and development expense for the years ended December 31, 2012 and 2011 was $45.2 million and $43.1 million, respectively, an increase of $2.1 million. The increase primarily was due to higher health economics and outcomes research and pharmacovigilance expenses. We also incurred expenses related to our prophylaxis and pediatric clinical trials, which began in 2012. The increase was partially offset by lower materials costs associated with DIFICID production prior to FDA approval in 2011. Research and development expense for the quarters ending December 31, 2012 and 2011 was $11.9 million and $14.0 million, respectively, a decrease of $2.1 million.
Selling, general and administrative expense for years ended December 31, 2012 and 2011 was $112.0 million and $80.6 million, respectively, an increase of $31.4 million. The increase primarily was due to our commercialization efforts for DIFICID which included a full year of expense in 2012. We also incurred higher compensation expense and higher legal and facilities expenses. SG&A expense for the quarters ending December 31, 2012 and 2011 was $31.2 million and $30.0 respectively, an increase of $1.2 million. In order to conform to our current period financial statement presentation, we reclassified two line items on our 2011 Consolidated Statements of Operations to separately identify co-promotion expenses with Cubist Pharmaceuticals, Inc. Previously, Cubist co-promotion expenses were included in our SG&A expense.
Co-promotion expenses with Cubist for the years ended December 31, 2012 and 2011 were $23.2 million and $6.6 million, respectively, an increase of $16.6 million. This increase was due to a full year of co-promotion expenses and included the year-one sales target bonus and gross profit share on sales above the target. Co-promotion expenses for the quarters ending December 31, 2012 and 2011 were $3.8 million and $3.6 million, respectively, an increase of $0.2 million.
For the year ended December 31, 2012, Optimer reported a net loss of $37.0 million, or $0.78 per share, on both a basic and diluted basis, as compared to net income for the year ended December 31, 2011 of $7.8 million, or $0.17 per share, on both a basic and diluted basis. Net income for the fourth quarter of 2012 was $1.0 million, or $0.02 per share, on a basic and diluted basis, as compared to net income for the fourth quarter of 2011 of $13.4 million, or $0.29 and $0.28 per share, on a basic and diluted basis, respectively. Net income in the fourth quarter of 2012 includes a gain of $31.5 million from the sale of our equity interest in Optimer Biotechnology, Inc. (OBI).
At December 31, 2012, Optimer held cash, cash equivalents and short-term investments of $124.0 million. This includes proceeds from the sale of our equity interest in OBI, which was completed in the fourth quarter.
Optimer had 47.8 million shares outstanding on December 31, 2012.
“Healthcare policy is shifting to new ways to control healthcare spending, particularly in hospitals. Many of our recent research initiatives, such as analyzing the cost burden of Clostridium difficile infection, are designed to assist hospitals to better understand the disease burden on their patients and institutions,” said Dr. McKinnell.
As of December 31, 2012:
- Inventory levels at wholesalers remain within the range of 14 to 28 days of demand
- Approximately 2,750 hospitals had ordered DIFICID
- About 83% of hospitals covered by Optimer have reordered DIFICID
- Approximately 1,000 hospitals are estimated to have placed DIFICID on formulary
As a result of the management changes announced yesterday and processes and procedures in connection therewith, we have determined that the filing of our Form 10-K will be delayed.
Conference Call and Webcast
The Company will host a conference call and webcast to discuss its fourth quarter and fiscal year 2012 financial results and provide a corporate update today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join “Optimer’s Financial Results Call.” The conference call will be webcast live under the Investors section of Optimer’s website at www.optimerpharma.com, where it will be archived for 30 days following the call.
About DIFICID® (fidaxomicin) Tablets
DIFICID is the first macrolide antibacterial drug indicated for Clostridium difficile-associated diarrhea (CDAD) to be approved in over 25 years in the U.S. It is indicated in the U.S. for the treatment of CDAD in adults 18 years of age or older. DIFICID is administered in 200 milligram tablets given orally, twice daily.
Important Safety Information for DIFICID
DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or to any of the excipients in the formulation. DIFICID should not be used for systemic infections. Only use DIFICID for infection proven, or strongly suspected, to be caused by C. difficile. Prescribing DIFICID in the absence of a proven, or strongly suspected, C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%) and neutropenia (2%).
Please visit www.DIFICID.com or call 855-DIFICID (343-4243) for full prescribing information for DIFICID.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older, and is commercializing DIFICID in the U.S. and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR(TM). The Company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem. Additional information can be found at http://www.optimerpharma.com.
Statements included in this press release that are not a description of historical facts are forward-looking statements, including, without limitation, statements related to the implementation and impact of Optimer’s commercialization strategy, Optimer’s pursuit of new indications for DIFICID, Optimer’s on-going education efforts regarding its patient access initiatives and the burden of Clostridium difficile infection and expansion of DIFICID sales or market potential. Words such as “expect,” “anticipate,” “will,” “could,” “would,” “project,” “intend,” “plan,” “believe,” “predict,” “estimate,” “should,” “may,” “potential,” “continue,” “ongoing” or variations of such words and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management’s expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer’s business including, without limitation, risks relating to: Optimer’s ability to continue to increase adoption and use of DIFICID, the implementation and success of DIFICID growth initiatives and entry into new markets, whether or not healthcare professionals will prescribe DIFICID, the extent to which DIFICID receives reimbursement coverage from healthcare payors and government agencies, the extent to which DIFICID will be accepted on additional hospital formularies and the timing of hospital formulary decisions, Optimer’s ability to successfully coordinate commercialization efforts with Cubist under its co-promotion agreement, whether Optimer will be able to realize expected benefits under its co-promotion agreement with Cubist and its collaboration agreements with other partners, the possibility of alternative means of preventing or treating CDAD impacting adoption and sales of DIFICID, Optimer’s ability, through its third-party manufacturers and logistics providers, to maintain a sufficient supply of DIFICID to meet demand, the effects of changes in Optimer’s management, the outcome of Optimer’s review of strategic alternatives including a possible sale of the Company, the potential for lawsuits and enforcement proceedings related to the previously disclosed investigations by U.S. authorities and other risks detailed in Optimer’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law.
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
Jason I. Spark, Senior Vice President
Optimer Pharmaceuticals, Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended Years Ended December 31, December 31, ------------ ------------ 2012 2011 2012 2011 ---- ---- ---- ---- (unaudited) (unaudited) Revenues: Product sales, net $16,820,952 $10,959,217 $62,417,155 $21,511,037 Contract revenue 2,694,724 53,584,000 39,112,168 122,749,000 Other - 73,139 2,106 718,336 Total revenues 19,515,676 64,616,356 101,531,429 144,978,373 Cost and expenses: Cost of product sales 1,364,656 909,843 5,486,239 1,525,798 Cost of contract revenue 1,652,008 3,310,821 6,462,939 7,584,353 Research and development 11,867,287 14,011,078 45,202,722 43,085,307 Selling, general and administrative 31,201,682 29,991,411 112,025,724 80,574,336 Co-promotion expenses with Cubist 3,750,000 3,641,161 23,190,629 6,569,921 --------- --------- ---------- --------- Total operating expenses 49,835,633 51,864,314 192,368,253 139,339,715 ---------- ---------- ----------- ----------- Gain (loss) from operations (30,319,957) 12,752,042 (90,836,824) 5,638,658 Gain on de-consolidation of OBI - - 23,782,229 - Gain on sale of OBI shares 31,500,606 - 31,500,606 - Equity in net loss of OBI - - (1,849,254) - Interest income (loss) and other, net (179,940) 63,337 136,269 290,870 -------- ------ ------- ------- Consolidated net gain (loss) 1,000,709 12,815,379 (37,266,974) 5,929,528 Net loss attributable to non-controlling interest - 538,892 280,344 1,892,096 Net gain (loss) attributable to Optimer Pharmaceuticals, Inc. $1,000,709 $13,354,271 $(36,986,630) $7,821,624 ========== =========== ============ ========== Net gain (loss) per share - basic $0.02 $0.29 $(0.78) $0.17 ===== ===== ====== ===== Net gain (loss) per share - diluted $0.02 $0.28 $(0.78) $0.17 ===== ===== ====== ===== Weighted average number of shares used to compute net gain (loss) per share - basic 47,742,372 46,668,310 47,331,510 45,622,168 ========== ========== ========== ========== Weighted average number of shares used to compute net gain (loss) per share - diluted 48,244,646 47,527,766 47,331,510 46,369,683 ========== ========== ========== ========== Optimer Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets December 31, December 31, 2012 2011 ---- ---- (unaudited) ASSETS Current assets: Cash and cash equivalents $119,444,586 $31,787,512 Short-term investments 4,556,329 78,791,066 Trade accounts receivable, net 7,119,089 6,563,645 Accounts receivable, other 2,391,071 52,289,290 Inventory 15,061,771 3,947,380 Prepaid expenses and other current assets 3,442,717 3,781,830 Total current assets 152,015,563 177,160,723 Property, equipment and other, net 4,338,720 2,590,715 Long-term investments 820,000 882,000 Deferred tax assets, non-current 890,843 - Other assets 1,362,196 1,389,734 --------- --------- Total assets $159,427,322 $182,023,172 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $7,166,127 $9,860,462 Accrued expenses 19,165,362 21,447,544 Deferred revenue 456,250 - Total current liabilities 26,787,739 31,308,006 Deferred rent 938,520 151,141 Income taxes payable, non-current 890,843 - Stockholders' equity 130,810,220 150,564,025 Total liabilities and stockholders' equity $159,427,322 $182,023,172 ============ ============
SOURCE Optimer Pharmaceuticals, Inc.